| Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory … CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling, GM Leung The Lancet 400 (10359), 1213-1222, 2022 | 212 | 2022 |
| Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong … CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling, GM Leung The Lancet Infectious Diseases 22 (12), 1681-1693, 2022 | 197 | 2022 |
| Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines CKH Wong, LY Mak, ICH Au, FTT Lai, X Li, EYF Wan, CSL Chui, ... Journal of Hepatology 77 (5), 1339-1348, 2022 | 41 | 2022 |
| Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study X Xiong, CKH Wong, ICH Au, FTT Lai, X Li, EYF Wan, CSL Chui, ... Thyroid 32 (5), 505-514, 2022 | 41 | 2022 |
| Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19) CKH Wong, KTK Lau, ICH Au, X Xiong, EHY Lau, BJ Cowling Clinical Infectious Diseases 74 (8), 1450-1458, 2022 | 39 | 2022 |
| Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study CKH Wong, KTK Lau, X Xiong, ICH Au, FTT Lai, EYF Wan, CSL Chui, X Li, ... PLoS medicine 19 (6), e1004018, 2022 | 33 | 2022 |
| Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study CKH Wong, KTK Lau, ICH Au, EHY Lau, LLM Poon, IFN Hung, ... The Lancet Infectious Diseases 23 (6), 683-695, 2023 | 30 | 2023 |
| Optimal timing of remdesivir initiation in hospitalized patients with coronavirus disease 2019 (COVID-19) administered with dexamethasone CKH Wong, KTK Lau, ICH Au, X Xiong, MSH Chung, EHY Lau, ... Clinical Infectious Diseases 75 (1), e499-e508, 2022 | 30 | 2022 |
| Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study CKH Wong, ICH Au, WY Cheng, KKC Man, KTK Lau, LY Mak, SL Lui, ... Alimentary Pharmacology & Therapeutics 56 (1), 121-130, 2022 | 22 | 2022 |
| Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients CKH Wong, DTW Lui, X Xiong, CSL Chui, FTT Lai, X Li, EYF Wan, ... BMC medicine 20 (1), 339, 2022 | 20 | 2022 |
| Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA. 2 wave: an observational study CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling, GM Leung medRxiv, 2022.05. 19.22275291, 2022 | 18 | 2022 |
| Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis DTW Lui, ICH Au, EHM Tang, CL Cheung, CH Lee, YC Woo, T Wu, ... EClinicalMedicine 50, 2022 | 16 | 2022 |
| Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and … CKH Wong, X Xiong, KTK Lau, CSL Chui, FTT Lai, X Li, EWY Chan, ... BMC medicine 20 (1), 119, 2022 | 16 | 2022 |
| Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 … CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling, GM Leung MedRxiv, 2022.05. 26.22275631, 2022 | 11 | 2022 |
| Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: propensity score analysis of a territory-wide … CKH Wong, DTW Lui, AYC Lui, ACY Kwok, MCH Low, KTK Lau, ICH Au, ... Diabetes & Metabolism 48 (1), 101307, 2022 | 10 | 2022 |
| Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or nirmatrelvir-ritonavir … DTW Lui, MSH Chung, EHY Lau, KTK Lau, ICH Au, CH Lee, YC Woo, ... JAMA Network Open 6 (5), e2314393-e2314393, 2023 | 9 | 2023 |
| Initiation of tocilizumab or baricitinib were associated with comparable clinical outcomes among patients hospitalized with COVID-19 and treated with dexamethasone CKH Wong, KTK Lau, ICH Au, X Xiong, MSH Chung, BYC Leung, ... Frontiers in Pharmacology 13, 866441, 2022 | 9 | 2022 |
| Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world … DTW Lui, EHM Tang, T Wu, ICH Au, CH Lee, YC Woo, KCB Tan, ... Cardiovascular Diabetology 22 (1), 40, 2023 | 8 | 2023 |
| Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong DTW Lui, T Wu, EHM Tang, ICH Au, CH Lee, YC Woo, KCB Tan, ... Diabetes Research and Clinical Practice 197, 110576, 2023 | 7 | 2023 |
| Evaluation of fracture risk among patients with type 2 diabetes and nonvalvular atrial fibrillation receiving different oral anticoagulants DTW Lui, E Ho Man Tang, ICH Au, T Wu, CH Lee, CK Wong, ... Diabetes Care 45 (11), 2620-2627, 2022 | 7 | 2022 |
